These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 15834297

  • 1. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA).
    Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R, Hennig M, Baurecht H, Parati G, Mancia G, Zanchetti A, ELSA Echocardiographic Substudy Group.
    J Hypertens; 2005 May; 23(5):1091-8. PubMed ID: 15834297
    [Abstract] [Full Text] [Related]

  • 2. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
    Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G.
    J Hypertens; 2007 Dec; 25(12):2463-70. PubMed ID: 17984668
    [Abstract] [Full Text] [Related]

  • 3. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
    Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid J, Rodicio J, Safar M, Eckes L, Ravinetto R.
    J Hypertens; 1998 Jul; 16(7):949-61. PubMed ID: 9794735
    [Abstract] [Full Text] [Related]

  • 4. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
    Zanchetti A, Bond MG, Hennig M, Tang R, Hollweck R, Mancia G, Eckes L, Micheli D, ELSA Investigators.
    J Hypertens; 2004 Jun; 22(6):1201-12. PubMed ID: 15167456
    [Abstract] [Full Text] [Related]

  • 5. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
    Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, European Lacidipine Study on Atherosclerosis investigators.
    Circulation; 2002 Nov 05; 106(19):2422-7. PubMed ID: 12417537
    [Abstract] [Full Text] [Related]

  • 6. Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study.
    Paliotti R, Ciulla MM, Hennig M, Tang R, Bond MG, Mancia G, Magrini F, Zanchetti A.
    J Hypertens; 2005 Jun 05; 23(6):1203-9. PubMed ID: 15894896
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
    Barrios V, Escobar C, Tomás JP, Calderon A, Echarri R.
    Clin Ther; 2008 Jan 05; 30(1):98-107. PubMed ID: 18343246
    [Abstract] [Full Text] [Related]

  • 8. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA).
    Giannattasio C, Failla M, Hennig M, Hollweck R, Laurent S, Mallion JM, Reid J, Safar M, Bond G, Zanchetti A, Mancia G.
    J Hypertens; 2005 Mar 05; 23(3):557-62. PubMed ID: 15716697
    [Abstract] [Full Text] [Related]

  • 9. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA).
    Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, Parati G, Facchetti R, Mancia G.
    Circulation; 2009 Sep 22; 120(12):1084-90. PubMed ID: 19738145
    [Abstract] [Full Text] [Related]

  • 10. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M, REGAAL Study Investigators.
    J Hypertens; 2002 Sep 22; 20(9):1855-64. PubMed ID: 12195129
    [Abstract] [Full Text] [Related]

  • 11. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.
    Agabiti-Rosei E, Ambrosioni E, Dal Palù C, Muiesan ML, Zanchetti A.
    J Hypertens; 1995 Nov 22; 13(11):1325-34. PubMed ID: 8984131
    [Abstract] [Full Text] [Related]

  • 12. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D, Malmqvist K, Held C, Kahan T.
    J Intern Med; 2007 May 22; 261(5):472-9. PubMed ID: 17444886
    [Abstract] [Full Text] [Related]

  • 13. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.
    Mancia G, Facchetti R, Parati G, Zanchetti A.
    Circulation; 2012 Jul 31; 126(5):569-78. PubMed ID: 22761453
    [Abstract] [Full Text] [Related]

  • 14. Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA).
    Zanchetti A.
    J Hypertens Suppl; 1995 Dec 31; 13(4):S35-9. PubMed ID: 8824685
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atheroscelerosis (ELSA).
    Zanchetti A.
    Blood Press Suppl; 1996 Dec 31; 4():30-5. PubMed ID: 8973780
    [Abstract] [Full Text] [Related]

  • 16. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients.
    Agabiti-Rosei E, Zulli R, Muiesan ML, Salvetti M, Rizzoni D, Corbellini C, Monteduro C.
    Blood Press; 1998 May 31; 7(3):160-9. PubMed ID: 9758086
    [Abstract] [Full Text] [Related]

  • 17. Lacidipine: a review of its use in the management of hypertension.
    McCormack PL, Wagstaff AJ.
    Drugs; 2003 May 31; 63(21):2327-56. PubMed ID: 14524737
    [Abstract] [Full Text] [Related]

  • 18. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA).
    Tang R, Hennig M, Thomasson B, Scherz R, Ravinetto R, Catalini R, Rubba P, Zanchetti A, Bond MG.
    J Hypertens; 2000 Feb 31; 18(2):197-201. PubMed ID: 10694188
    [Abstract] [Full Text] [Related]

  • 19. Changes in left ventricular geometry during antihypertensive treatment.
    Salvetti M, Paini A, Bertacchini F, Stassaldi D, Aggiusti C, Agabiti Rosei C, Bassetti D, Agabiti-Rosei E, Muiesan ML.
    Pharmacol Res; 2018 Aug 31; 134():193-199. PubMed ID: 29959031
    [Abstract] [Full Text] [Related]

  • 20. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K.
    Circulation; 2004 Sep 14; 110(11):1456-62. PubMed ID: 15326072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.